05.07.19
Allergan
1Q Revenues: $3.6 billion (-2%)
1Q Loss: $2.4 billion (loss of $284 million 1Q18)
Comments: U.S. Specialized Therapeutics revenues were $1.5 billion in the quarter, down 2%. BOTOX Therapeutic, BOTOX Cosmetic and JUVÉDERM Collection growth was partially offset by a decline in CoolSculpting sales, lower RESTASIS revenues due to lower net pricing, as well as the divestiture of the Company's Medical Dermatology business on September 2018. BOTOX Therapeutic sales in the quarter were $397.6 million, up 6%. RESTASIS sales were $231.7 million, down 9%. ALPHAGAN/COMBIGAN sales were $83.0 million, down 1%. OZURDEX revenues were $30.3 million, up 19%. U.S. General Medicine revenues were $1.3 billion, up 2%, primarily due to growth in VRAYLAR and Lo LOESTRIN, partially offset by lower revenues from products that lost exclusivity. VRAYLAR revenues were $143.7 million, up 70%. VIIBRYD/FETZIMA sales were $85.0 million, up 19%. LINZESS sales were $161.3 million, up 1%. Lo LOESTRIN sales were $125.8 million, up 10%. BYSTOLIC/BYVALSON sales were $128.3 million, down 3%.
1Q Revenues: $3.6 billion (-2%)
1Q Loss: $2.4 billion (loss of $284 million 1Q18)
Comments: U.S. Specialized Therapeutics revenues were $1.5 billion in the quarter, down 2%. BOTOX Therapeutic, BOTOX Cosmetic and JUVÉDERM Collection growth was partially offset by a decline in CoolSculpting sales, lower RESTASIS revenues due to lower net pricing, as well as the divestiture of the Company's Medical Dermatology business on September 2018. BOTOX Therapeutic sales in the quarter were $397.6 million, up 6%. RESTASIS sales were $231.7 million, down 9%. ALPHAGAN/COMBIGAN sales were $83.0 million, down 1%. OZURDEX revenues were $30.3 million, up 19%. U.S. General Medicine revenues were $1.3 billion, up 2%, primarily due to growth in VRAYLAR and Lo LOESTRIN, partially offset by lower revenues from products that lost exclusivity. VRAYLAR revenues were $143.7 million, up 70%. VIIBRYD/FETZIMA sales were $85.0 million, up 19%. LINZESS sales were $161.3 million, up 1%. Lo LOESTRIN sales were $125.8 million, up 10%. BYSTOLIC/BYVALSON sales were $128.3 million, down 3%.
